Maxcyte (MXCT) Non-Current Deffered Revenue (2021 - 2022)
Maxcyte (MXCT) reported Non-Current Deffered Revenue of $344600.0 for Q3 2022, down 23.46% on a QoQ basis from $450200.0 in Q4 2021.
Maxcyte (MXCT) has 2 years of Non-Current Deffered Revenue data on file, last reported at $344600.0 in Q3 2022.
- Quarterly Non-Current Deffered Revenue changed N/A year-over-year to $344600.0 in Q3 2022, while the trailing twelve-month figure through Sep 2022 was $344600.0 (changed N/A YoY) and the FY2021 annual result came in at $450200.0, changed N/A from the prior year.
- Non-Current Deffered Revenue eased to $344600.0 in Q3 2022 per MXCT's latest filing, from $450200.0 in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $450200.0 in Q4 2021 and bottomed at $344600.0 in Q3 2022.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | - |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | - |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | - |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | - |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | - |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 512.79 Mn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | - |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | - |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | - |
| 10 | Maxcyte | 129.85 Mn | 129.85 Mn | 8.08 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | 344,600.00 |
| Dec 31, 2021 | 450,200.00 |